Loading clinical trials...

Phase IIT Trial of SNA014 | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGEARLY_PHASE1

Phase IIT Trial of SNA014

Clinical Study of 68GA-labeled Claudin 18.2 Developer Combined with PET/CT for Imaging of Gastric or Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer

NCT06646783•SmartNuclide Biopharma

View on ClinicalTrials.gov

Summary

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for gastric or gastroesophageal junction

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age range of 18 to 75 years old (including boundary values);
•Individuals with behavioral capacity who voluntarily participate in this clinical study and sign an informed consent form (ICF);
•Diagnosed G/GEJ adenocarcinoma and pancreatic cancer;
•Gastroscopy/CT/MRI/PET-CT examination results within the past month (if any);
•Pathological test results and Claudin18.2 immunohistochemistry results within the past year (if available).

Exclusion Criteria

•Merge patients with other clearly diagnosed malignant tumors:
•Uncontrolled severe infections or individuals with other serious illnesses;
•Those with an expected survival period of less than or equal to three months;
•Pregnant or lactating patients, as well as reproductive age patients who refuse to take appropriate contraceptive measures during this trial;
•investigators determine that patients who are not suitable to participate in this study;

Locations (1)

The First Affiliated Hospital of Soochow University

Jiangsu, Province, China

Key Dates

Start Date

October 20, 2024

Primary Completion Date

October 20, 2025

Completion Date

November 20, 2025

Last Updated

October 17, 2024

Enrollment

ESTIMATED participants

Conditions

Adenocarcinoma of the StomachAdenocarcinoma of GE JunctionPancreatic Cancer Stage

Interventions

[68Ga]Ga-NODAGA-SNA014

DRUG

Contacts

Miao liyan Chief Pharmacist, doctorate

CONTACT

0512-679-72858 miaolysuzhou@163.com

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

NCT05254171

Pancreatic Cancer MetastaticPancreatic Ductal Adenocarcinoma+1 more

View study

RECRUITINGPHASE2

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

NCT05729646

Adenocarcinoma of the StomachAdenocarcinoma of Esophagogastric Junction+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 17, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phase IIT Trial of SNA014

Inclusion Criteria

Exclusion Criteria

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)